Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD3/MUC1-armed cytokine induced killer cells - Benhealth Biopharmaceutical

Next Previous
Search
Drug Profile

Anti-CD3/MUC1-armed cytokine induced killer cells - Benhealth Biopharmaceutical

Alternative Names: Activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody; Anti-CD3/MUC1 antibody-armed PD-1 inhibitor-induced cytokine-induced killer cells; Anti-CD3/MUC1-armed PD-1 inhibitor-induced CIK cells; PD-1 activated CIK armed with anti-CD3/Anti-MUC1 bispecific antibody

Latest Information Update: 23 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Benhealth Biopharmaceutical
  • Class Bispecific antibodies; Cell therapies; Drug conjugates; Immunotherapies
  • Mechanism of Action Cell replacements; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Liver cancer

Most Recent Events

  • 23 Feb 2022 Phase II trial is still ongoing for Liver cancer (Late-stage disease) in China (NCT03146637)
  • 04 Jun 2021 Adverse events and efficacy data from a phase II trial in Liver cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
  • 19 Oct 2020 Benhealth Biopharmaceutical withdraws a phase II trial in Gastric cancer (Late-stage disease) in China prior to enrolment (Parenteral) (NCT03554395)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top